Validated myeloma survival kinases: functional categories
| GenBank accession no. . | Symbol . | Description . | Vulnerability, BZ-score . | Lethal with 2+ unique siRNA in these myeloma lines . | ||
|---|---|---|---|---|---|---|
| KMS11 . | INA6 . | JJN3 . | ||||
| Cell-cycle regulation | ||||||
| NM_005030 | PLK1 | Pololike kinase 1 | −11.5 | −7.7 | −6.8 | KMS11, INA6, JJN3 |
| NM_001787 | CDC2L1 | Cell division cycle 2-like 1 (PITSLRE proteins) | −9.3 | −2.9 | −3.0 | KMS11, JJN3 |
| NM_004217 | AURKB | Aurora kinase B | −6.9 | −3.8 | −6.0 | KMS11, JJN3 |
| NM_003600 | AURKA | Aurora kinase A (serine/threonine kinase 6) | −6.3 | −3.3 | −4.3 | KMS11, INA6, JJN3 |
| NM_005255 | GAK | Cyclin G associated kinase | −4.6 | 0.7 | −3.8 | KMS11 |
| NM_003936 | CDK5R2 | Cyclin-dependent kinase 5, regulatory subunit 2 (p39) | −4.2 | −0.5 | −3.5 | KMS11, JJN3 |
| Proto-oncogenes: proliferation or survival | ||||||
| NM_002005 | FES | Feline sarcoma oncogene | −9.1 | −0.8 | −3.8 | KMS11, JJN3 |
| NM_005163 | AKT1 | v-akt murine thymoma viral oncogene homolog 1 | −6.9 | 0.2 | −4.9 | KMS11, JJN3 |
| VEGF signaling | ||||||
| NM_182925 | FLT4 | fms-related tyrosine kinase 4 (VEGFR3) | −6.2 | −2.5 | −5.3 | KMS11, JJN3 |
| G-protein receptor signaling | ||||||
| NM_002082 | GRK6 | G protein–coupled receptor kinase 6 | −6.4 | 0.0 | −3.1 | KMS11 |
| JNK/NF-κB activation | ||||||
| NM_002741 | PKN1 | Protein kinase N1 (protein kinase C-like 1) | −8.7 | −5.9 | −5.6 | KMS11, INA6, JJN3 |
| RNA/DNA surveillance (nonsense-mediated decay) | ||||||
| NM_014006 | SMG1 | PI-3-kinase-related kinase SMG-1 (LIP) | −11.2 | −2.7 | −5.2 | KMS11, JJN3 |
| Metabolic regulation | ||||||
| NM_033498 | HK1 | Hexokinase 1 | −9.9 | −6.7 | −5.6 | KMS11, INA6, JJN3 |
| NM_013410 | AK3L1 | Adenylate kinase 3 like 1 | −3.6 | 0.2 | −5.5 | KMS11, JJN3 |
| Novel | ||||||
| NM_005781 | TNK2 | Activated Cdc42-associated kinase 1 (tyrosine kinase, nonreceptor, 2) | −7.8 | −1.6 | −2.6 | KMS11 |
| GenBank accession no. . | Symbol . | Description . | Vulnerability, BZ-score . | Lethal with 2+ unique siRNA in these myeloma lines . | ||
|---|---|---|---|---|---|---|
| KMS11 . | INA6 . | JJN3 . | ||||
| Cell-cycle regulation | ||||||
| NM_005030 | PLK1 | Pololike kinase 1 | −11.5 | −7.7 | −6.8 | KMS11, INA6, JJN3 |
| NM_001787 | CDC2L1 | Cell division cycle 2-like 1 (PITSLRE proteins) | −9.3 | −2.9 | −3.0 | KMS11, JJN3 |
| NM_004217 | AURKB | Aurora kinase B | −6.9 | −3.8 | −6.0 | KMS11, JJN3 |
| NM_003600 | AURKA | Aurora kinase A (serine/threonine kinase 6) | −6.3 | −3.3 | −4.3 | KMS11, INA6, JJN3 |
| NM_005255 | GAK | Cyclin G associated kinase | −4.6 | 0.7 | −3.8 | KMS11 |
| NM_003936 | CDK5R2 | Cyclin-dependent kinase 5, regulatory subunit 2 (p39) | −4.2 | −0.5 | −3.5 | KMS11, JJN3 |
| Proto-oncogenes: proliferation or survival | ||||||
| NM_002005 | FES | Feline sarcoma oncogene | −9.1 | −0.8 | −3.8 | KMS11, JJN3 |
| NM_005163 | AKT1 | v-akt murine thymoma viral oncogene homolog 1 | −6.9 | 0.2 | −4.9 | KMS11, JJN3 |
| VEGF signaling | ||||||
| NM_182925 | FLT4 | fms-related tyrosine kinase 4 (VEGFR3) | −6.2 | −2.5 | −5.3 | KMS11, JJN3 |
| G-protein receptor signaling | ||||||
| NM_002082 | GRK6 | G protein–coupled receptor kinase 6 | −6.4 | 0.0 | −3.1 | KMS11 |
| JNK/NF-κB activation | ||||||
| NM_002741 | PKN1 | Protein kinase N1 (protein kinase C-like 1) | −8.7 | −5.9 | −5.6 | KMS11, INA6, JJN3 |
| RNA/DNA surveillance (nonsense-mediated decay) | ||||||
| NM_014006 | SMG1 | PI-3-kinase-related kinase SMG-1 (LIP) | −11.2 | −2.7 | −5.2 | KMS11, JJN3 |
| Metabolic regulation | ||||||
| NM_033498 | HK1 | Hexokinase 1 | −9.9 | −6.7 | −5.6 | KMS11, INA6, JJN3 |
| NM_013410 | AK3L1 | Adenylate kinase 3 like 1 | −3.6 | 0.2 | −5.5 | KMS11, JJN3 |
| Novel | ||||||
| NM_005781 | TNK2 | Activated Cdc42-associated kinase 1 (tyrosine kinase, nonreceptor, 2) | −7.8 | −1.6 | −2.6 | KMS11 |